Centre De Cancerologue Du Grand Montpellier — Clinical Trial Site

68 Registered trials

31 Currently recruiting

Organisation

Centre De Cancerologue Du Grand Montpellier

Location

Montpellier, France

Identifier

ORG-100041704

Address

25 Rue De Clementville, 34070, France

Departments

03306
2302: Clinique Clementville
2309:Oncologie Médicale
2311 Oncology Medical
4410:Medical Oncology
Breast Oncology
Centre de Cancérologie
Centre de Cancérologie du Grand Montpellier
Clinical Research
Clinique privée
FRA005: NA
medical oncology
Medical Oncology Department
N/A
NA
Oncologie
Oncologie Médicale
Oncology
Oncology Department
Oncology-Radiotherapy
Oncology-Radiotherapy Unit
Pneumology
Service d'Oncologie
Service d'oncologie medicale
Service De Radiotherapie

Clinical trials at this site (68)

Search interface

A clinical study of sac-TMT in people with breast cancer (MK-2870-032) Recruiting

2024-520190-12-00 Breast Cancer: triple negative breast cancer (TNBC) and 5 2025-11-10
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an… Recruiting

2024-516162-11-00 Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3 5 2025-07-14
Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in … Recruiting

2024-514465-18-00 Advanced or Metastatic Non-Squamous NSCLC 9 2025-04-23
Comparison between ABP 234 and Keytruda® (Pembrolizumab) Recruiting

2024-514304-14-00 Advanced or Metastatic Non-squamous Non-Small Cell Lung 1 2024-10-08
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B… Recruiting

2022-503114-23-00 Breast Cancer 3 2023-12-19
This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a Phase 2 evaluation of elacestran… Recruiting

2024-512878-98-00 Brain Metastasis from Estrogen Receptor Positive, HER-2 9 2023-05-16
PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer Recruiting

2024-512173-27-00 Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible f 5 2019-03-21
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Part… Ended

2023-506146-23-00 Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the 4 2025-11-17
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended

2024-512925-95-00 Advanced/Metastatic Breast Cancer 5 2025-05-16
A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended

2023-507333-17-00 HER2-low, Hormone Receptor Positive, Metastatic Breast 5 2024-04-15
A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended

2023-503827-25-01 Non-Small Cell Lung Cancer (NSCLC) 5 2024-02-16
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD… Ended

2022-501343-33-00 Biochemically recurrent prostate cancer 5 2023-10-18
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C… Ended

2023-505552-22-00 Stage I-III Triple-negative Breast Cancer with residual 5 2023-02-24
Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended

2023-509429-37-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5 2022-10-03
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously U… Ended

2023-504194-21-00 PD-L1 Positive Metastatic Triple-Negative Breast Cancer 5 2022-09-13
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable… Ended

2023-504195-14-00 PD-L1-negative metastatic triple-negative breast cancer 5 2022-08-31
Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea… Ended

2024-514630-21-00 HER2 positive (HER2+), Hormone Receptor positive (HR+) 4 2022-08-11
A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can… Ended

2023-503826-37-00 Unresectable locally-advanced or metastatic HER2+ breas 5 2022-02-11